Paul Mainwaring Clinical Oncology Society of Australia Annual Scientific Meeting 2017

Abstracts this author is presenting:

• Overall survival (OS) in METEOR, a randomised phase 3 trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma (RCC) — Best of Best Poster discussion - Clinical Research and Supportive Care
• Regional differences in the phase 3 METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC) — Poster Session 1